Abivax (ABVX) Share-based Compensation (2024 - 2026)

Abivax's Share-based Compensation history runs 3 years deep, the most recent figure standing at $26.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 436.68% year-over-year to $26.5 million in Q1 2026; TTM through Mar 2026 was $62.1 million, a 201.76% increase from a year earlier, with the FY2025 full-year figure at $41.2 million, up 88.24% from the prior year.
• Share-based Compensation advanced to $26.5 million in Q1 2026 per ABVX's latest filing, from $15.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $26.5 million in Q1 2026 and bottomed at $4.8 million in Q4 2024.
• The 3-year median for Share-based Compensation is $6.3 million (2024), against an average of $9.9 million.
• Across the five-year window, Share-based Compensation declined 21.11% in 2025 and surged 436.68% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $4.8 million in 2024, then surged by 215.28% to $15.0 million in 2025, then soared by 76.28% to $26.5 million in 2026.
• Per Business Quant, the three latest ABVX Share-based Compensation figures stand at $26.5 million (Q1 2026), $15.0 million (Q4 2025), and $13.4 million (Q3 2025).